EUCTR2018-002502-31-GB进行中（未招募）1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A - FANCOLEN-II
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. FA as diagnosed by chromosomal fragility assay of cultured lymphocytes in the presence of DEB or a similar DNA-crosslinking agent
- •2. Patients of the complementation group FA-A
- •3. Minimum age: 1 year and a minimum weight of 8 kg.
- •4. Maximum age: 17 years
- •5. At least 30 CD34+ cells/µL are determined in one BM aspiration within 3 months prior to CD34+ cell collection OR (see subsequent criterion)
- •6. If the number of CD34+ cells/µL in BM is in the range of 10–29, PB parameters should meet two of the three following criteria:
- •Hemoglobin: =11g/dL
- •Neutrophils: =900 cells/µL
- •Platelets: =60,000 cells/µL
- •7. Provide informed consent in accordance with current legislation
- •8. Women of childbearing age must have a negative urine pregnancy test at the baseline visit, specifically within 14 days prior to infusion of IMP and must accept the use of an effective contraception method during participation in the trial as defined in the note below.
- •Note: Female patients of childbearing potential (e.g., are menstruating or could reach menarche during the study) should be counselled on the need for contraception should they be sexually active or, in the opinion of the Investigator, likely to be sexually active. Such subjects must agree to the use of contraception as defined in the subsequent paragraph. Male patients who are sexually active must agree to use a condom during intercourse for the duration of their participation in the study.
- •Acceptable methods of contraception for female subjects of childbearing potential include the following:
- •- male or female condom with or without spermicide;
- •- cap, diaphragm or sponge with spermicide;
- •- intrauterine device (IUD);
- •- bilateral tubal occlusion;
- •- vasectomised partner;
- •- sexual abstinence.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with an available and medically eligible HLA-identical sibling donor
- •2. Evidence of myelodysplastic syndrome or leukaemia, or cytogenetic abnormalities other than those reported as variant(s) of normal in BM aspirate analysis. This assessment should be made by valid studies conducted within the 3 months before the patient enters the clinical trial
- •3. Patients with somatic mosaicism associated with stable or improved counts in all PB cell lineages (If T-lymphocyte chromosomal fragility analysis indicates potential mosaicism, a medically significant decrease in at least one blood lineage over time must be documented to enable eligibility)
- •4. Lansky performance index =60%
- •5. Any concomitant disease or condition that, in the opinion of the Principal Investigator, deems the patient unfit to participate in the trial
- •6. Pre-existing sensory or motor impairment =grade 2 according to the criteria of the National Cancer Institute (NCI)
- •7. Pregnant or breastfeeding women
- •8. Hepatic dysfunction as defined by either:
- •Bilirubin > 3.0× the upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) >5.0× ULN
- •Aspartate aminotransferase (AST) >5.0× ULN.
- •For subjects with bilirubin, ALT or AST above ULN, a workup to identify the etiology of liver abnormality should be conducted prior to confirmation of eligibility as stipulated in exclusion criterion 5, including evaluation of viral hepatitis, iron overload, drug injury or other causes.
- •9. Renal dysfunction requiring either hemodialysis or peritoneal dialysis
- •10. Pulmonary dysfunction as defined by either:
- •Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection)
- •Oxygen saturation (by pulse oximetry) <90%.
- •11. Evidence of active metastatic or locoregionally advanced malignancy for which survival is anticipated to be less than 3 years
- •12. Subject is receiving androgens (i.e., danazol, oxymetholone)
- •13. Subject is receiving other investigational therapy for treatment/prevention of FA-associated bone marrow failure.
研究者
相似试验
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2, 4, 5 and 6MedDRA version: 16.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 16.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-GBMerck Sharp & Dohme Corp.100
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-ESRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
Clinical Trial testing the combination of MK-5172 with/without MK-8742 and/or Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2/4/5/6MedDRA version: 17.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,100
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2MedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-ESMerck Sharp & Dohme Corp.70
进行中（未招募）
1 期
Pembrolizumab (MK-3475) and Pembrolizumab in combination with other agents in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapyon-Muscle Invasive Bladder Cancer (NMIBC)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004026-17-FIMerck Sharp & Dohme LLC320